Harvard

Health Tech By Casey Ross

The sale of Watson Health assets ends a dark chapter for IBM. For its buyer, the opportunity looks brighter

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Health Tech By Casey Ross

Once billed as a revolution in medicine, IBM’s Watson Health is sold off in parts

Pharmalot By Ed Silverman

Pharmalittle: Alzheimer’s patient groups to protest Medicare plan for Biogen drug; cancer combo treatments are questioned

First Opinion By Chenery Lowe, Liesl Broadbridge and Laynie Dratch

What genetic counselors can teach the CDC about communicating uncertainty

First Opinion By Cynda Hylton Rushton, Ian Wolfe and Tener Goodwin Veenema

It’s staff, not stuff: Applying crisis standards of care to allocating health care workers

Health Tech By Mohana Ravindranath

For doctors drowning in emails, one health system’s new strategy: pay for replies

The Pharmalot View By Ed Silverman

If the Biogen CEO were truly ‘courageous,’ he would live with the Medicare decision